 VANCOUVER, Washington, May 27, 2021 GLOBE NEWSWIRE -- CytoDyn Inc. OTC.QB: CYDY, CytoDyn or the Company, a late-stage biotechnology company developing VyrologixTM leronlimab-PRO 140, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that its Brazilian distribution partner, Biomm S.A. BVMF: BIOM3, plans to submit an authorization request to the Brazilian National Health Surveillance Agency ANVISA in the next few days to conduct two Phase 3 clinical trials of leronlimab in Brazil for COVID-19. The two Phase 3 trials consist of trials for each severe and critically ill COVID-19 patients. Once approved by ANVISA, the Phase 3 trials will be conducted by Albert Einstein Israelite Hospital, an Academic Research Organization in Brazil. 